The growth of the vaccine technologies market is driven by rise in prevalence of infectious diseases, growing trend towards preventive healthcare, and government immunization programs and initiatives.

The First in China! BLA Submitted for Luzhu Biotech's Recombinant Herpes Zoster Vaccine Expected to Be Launched in 2026 HONG KONG ...

The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...

Trump has shut down the USAID work saying that it was not aligned with American strategic interests and wastes money.

Hexaplex' Vaccine Aims to Boost Flu Protection Feb. 26, 2024 — A research team has developed a recombinant protein flu vaccine candidate. It utilizes a nanoliposome vaccine platform that ...

Shingrix is a recombinant protein subunit-based vaccine and is generally used in favour of an older shingles vaccine – Merck & Co's Zostavax – which is cased on a live, attenuated virus.

This is a valuable study on the efficacy of a live attenuated vaccine that was tested in different animal ... Half-well protein high-binding 96-well plates (Greiner) were coated with recombinant ...

Scientists have uncovered a blood-based molecular signature that can predict vaccine durability. Could this change ...

North America preventive vaccines market is projected to grow by 6.3% annually in the forecast period and reach $46.90 billion by 2032, driven by the rising prevalence of several ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 62 tables and 55 figures, this 142-page report ?Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, ...

Background Because inactivated trivalent influenza vaccines (TIVs) contain 1 influenza B strain, whereas 2 lineages may co-circulate, B lineage mismatch is frequent. We assessed an inactivated ...